Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 9, Issue 5, 2007, Pages 724-732

  Bebakar, Wan Mohamad Wan ^a   Chow, C C ^b   Kadir, K A ^c   Suwanwalaikorn, S ^d   Vaz, J A ^e   Bech, O M ^e  

^a HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^e Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

Author keywords

Biphasic insulin aspart; Insulin initiation; OAD failures; Pre mixed insulin analogue; Type 2 diabetes

Indexed keywords

BIGUANIDE DERIVATIVE; BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREND STUDY; WEIGHT GAIN;

EID: 34547883494     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00743.x     Document Type: Article

References (22)

1. International Diabetes Federation. Diabetes Atlas, 2nd edn. International Diabetes Federation, Brussels, Belgium, 2003.
2. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes -Practical Targets and Treatments, 4th edn. International Diabetes Federation, Western Pacific Region, and International Diabetes Institute, Melbourne, Australia, 2005.
3. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
4. Weatherspoon LJ, Kumanyika SK, Ludlow R, Schatz D. Glycemic control in a sample of black and white clinic patients with NIDDM. Diabetes Care 1994; 17: 1148-1153.
5. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004; 27: 17-20.
6. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study. XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabet Med 1994; 11: 670-677.
7. Agrawal L, Emanuele NV, Abraira C et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 1998; 21: 510-515.
8. Karalliedde J, Smith A, Viberti G. Determinants of response to insulin therapy following failure of oral agents in type 2 diabetes. Diabetes Care 2005; 28: 2589 -2590.
9. Bradley C. Diabetes treatment satisfaction questionnaire (DTSQ). In: Bradley C ed. Handbook of Psychology and Diabetes. Chur: Harwood, 1994; 111-132.
10. Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart. Diabetologia 1998; 41 (Suppl. 1): 49.
11. Jacobsen V, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
12. Raz I, Weinstein J, Hershkovits TA, Menuchin O, Abraham Z, Lindholm A. Add-on of insulin or a second oral agent? Evaluation of premixed insulin aspart in combination with repaglinide, glibenclamide, metformin and rosiglitazone. Diabetologia 2002; 45 (Suppl. 2): A263.
13. Kvapil M, Swatko A, Ostergaard AH, Shestakova M. Biphasic insulin aspart 30 combined with metformin provides better glycaemic control in poorly controlled type 2 diabetic patients. Diabetes 2002; 51 (Suppl. 2): A104.
14. Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003; 25: 3109-3123.
15. Raz I, Stranks S, Filipczak R et al. In inadequately controlled patients with type 2 diabetes, biphasic insulin aspart 30 combined with pioglitazone provides better glycaemic control than biphasic insulin aspart 30 monotherapy or pioglitazone/sulphonylurea combination. Diabetes 2003; 52 (Suppl. 1): A453.
16. Eppens MC, Craig ME, Jones TW, Silink M, Ong S, Ping YJ. The International Diabetes Federation Western Pacific Region Steering Committee. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care and complications. Curr Med Res Opin 2006; 22: 1013-1020.
17. Chuang LM, Tsai ST, Huang BY, Tai TY. Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia -a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 19: 978-985.
18. Pan CY. Current status of diabetes care in Asia at the primary care level (Abstract presented at the 5th IDF-WPR Congress, Beijing, China). Diabetes Res Clin Pract 2002; 56 (Suppl. 1): S23.
19. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
20. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
21. Polonsky WH, Jackson RA. What's so tough about talking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diab 2004; 22: 147-150.
22. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238-2243.